Who to call at Takis S.r.l, and when
Fundz watches for the moments Takis S.r.l starts buying, and tells you who to reach.
- An alert the day Takis S.r.l raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Takis S.r.l, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Takis S.r.l. With Fundz connected, it knows.
Takis S.r.l. partners with Sapienza University and Tethis to enhance HER3-targeted therapies for lung cancer.
Contract Type
partnership
Description
A new partnership has been formed between Takis S.r.l., the Department of Clinical and Molecular Medicine of Sapienza University of Rome, and Tethis to accelerate research on HER3-targeted therapies. The collaboration aims to develop innovative treatments and companion diagnostics for lung cancer patients as part of the HERCART project.
Quick answer
Takis S.r.l. partners with Sapienza University and Tethis to enhance HER3-targeted therapies for lung cancer. (October 3, 2025). Takis S.r.l is based in Rome, Lazio, Italy.
- What agreement did Takis S.r.l announce on October 3, 2025?
- A new partnership has been formed between Takis S.r.l., the Department of Clinical and Molecular Medicine of Sapienza University of Rome, and Tethis to accelerate research on HER3-targeted therapies. The collaboration aims to develop innovative treatments and companion diagnostics for lung cancer patients as part of the HERCART project.
- What does Takis S.r.l do?
- Takis S.r.l. is a biopharmaceutical company focused on developing innovative therapies and diagnostics for cancer treatment.
- Where is Takis S.r.l based?
- Takis S.r.l is based in Rome, Lazio, Italy.
Source: Fundz verified event record.
Agreement Insights
What this usually meansTakis S.r.l signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.